KR20210135530A - Flna-결합 화합물 및 이의 하이드로클로라이드 염의 고체 다형체 - Google Patents

Flna-결합 화합물 및 이의 하이드로클로라이드 염의 고체 다형체 Download PDF

Info

Publication number
KR20210135530A
KR20210135530A KR1020217030333A KR20217030333A KR20210135530A KR 20210135530 A KR20210135530 A KR 20210135530A KR 1020217030333 A KR1020217030333 A KR 1020217030333A KR 20217030333 A KR20217030333 A KR 20217030333A KR 20210135530 A KR20210135530 A KR 20210135530A
Authority
KR
South Korea
Prior art keywords
crystalline
methyl
triazaspiro
decan
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217030333A
Other languages
English (en)
Korean (ko)
Inventor
마이클 잠루트
린지 번즈 바비어
숀 앤서니 쿠체라
Original Assignee
페인 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페인 테라퓨틱스, 인코포레이티드 filed Critical 페인 테라퓨틱스, 인코포레이티드
Publication of KR20210135530A publication Critical patent/KR20210135530A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020217030333A 2019-02-21 2020-02-21 Flna-결합 화합물 및 이의 하이드로클로라이드 염의 고체 다형체 Ceased KR20210135530A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962808609P 2019-02-21 2019-02-21
US62/808,609 2019-02-21
PCT/US2020/019305 WO2020172584A1 (en) 2019-02-21 2020-02-21 Solid polymorphs of a flna-binding compound and its hydrochloride salts

Publications (1)

Publication Number Publication Date
KR20210135530A true KR20210135530A (ko) 2021-11-15

Family

ID=72141575

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217030333A Ceased KR20210135530A (ko) 2019-02-21 2020-02-21 Flna-결합 화합물 및 이의 하이드로클로라이드 염의 고체 다형체

Country Status (10)

Country Link
US (4) US11370791B2 (https=)
EP (1) EP3927707A4 (https=)
JP (2) JP2022523196A (https=)
KR (1) KR20210135530A (https=)
CN (2) CN114072406B (https=)
AU (1) AU2020224678B2 (https=)
BR (1) BR112021016622A2 (https=)
CA (1) CA3131146A1 (https=)
IL (1) IL285763A (https=)
WO (1) WO2020172584A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020172584A1 (en) 2019-02-21 2020-08-27 Pain Therapeutics, Inc. Solid polymorphs of a flna-binding compound and its hydrochloride salts
US20220233512A1 (en) * 2020-11-03 2022-07-28 Cassava Sciences, Inc. Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
US8653068B2 (en) * 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US9340558B2 (en) * 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
US8614324B2 (en) * 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
WO2010051497A1 (en) * 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a binding anti-inflammatory and analgesic
EP2549873A1 (en) * 2010-03-25 2013-01-30 Merck Sharp & Dohme Corp. Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
WO2014012054A1 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
EP2882428B1 (en) * 2012-07-13 2019-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
US9433604B2 (en) * 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
WO2020172584A1 (en) 2019-02-21 2020-08-27 Pain Therapeutics, Inc. Solid polymorphs of a flna-binding compound and its hydrochloride salts

Also Published As

Publication number Publication date
JP2022523196A (ja) 2022-04-21
WO2020172584A1 (en) 2020-08-27
US12391693B2 (en) 2025-08-19
AU2020224678A1 (en) 2021-09-16
US20240400566A1 (en) 2024-12-05
JP2024054139A (ja) 2024-04-16
US20220340574A1 (en) 2022-10-27
CN114072406B (zh) 2025-03-18
EP3927707A4 (en) 2022-11-09
US12065440B2 (en) 2024-08-20
US11370791B2 (en) 2022-06-28
US20200270250A1 (en) 2020-08-27
CN114072406A (zh) 2022-02-18
CN120004896A (zh) 2025-05-16
AU2020224678B2 (en) 2024-03-14
NZ779310A (en) 2024-01-26
BR112021016622A2 (pt) 2021-11-03
IL285763A (en) 2021-10-31
EP3927707A1 (en) 2021-12-29
CA3131146A1 (en) 2020-08-27
US20250084083A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
US12391693B2 (en) Solid polymorphs of a FLNA-binding compound and its hydrochloride salts
US20250161292A1 (en) Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
WO2010139979A2 (en) Processes for preparing crystalline forms
US10071999B2 (en) Crystalline forms of (3-amino-oxetan-3-ylmethyl)-[2-(5,5-dioxo-5,6,7,9-tetrahydro-5lambda*6*-thia-8-aza-benzocyclohepten-8-yl)-6-methyl-quinazolin-4-yl]-amine
KR20230038229A (ko) 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도
EA030142B1 (ru) Соли дазатиниба
JP2025148406A (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
EP3495364A1 (en) Novel crystal form of jak1-selective inhibitor, and manufacturing method and application thereof
US11091494B2 (en) Crystal form of acalabrutinib and preparation method and use thereof
KR101852226B1 (ko) 오타믹사반의 벤조산염
US11136332B2 (en) Morphic forms of marizomib and uses thereof
US9643950B2 (en) Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
KR102858471B1 (ko) Lta4h 저해제의 결정질 형태
US20230105181A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
WO2026072992A1 (en) Salts and solid forms of muscarinic receptor agonists

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000